Analyst Price Targets — DYN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 2, 2026 10:37 pm | Keay Nakae | Chardan Capital | $38.00 | $16.15 | StreetInsider | Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN) |
| March 2, 2026 4:12 pm | Michael E Ulz | Morgan Stanley | $47.00 | $15.68 | StreetInsider | Dyne Therapeutics (DYN) PT Lowered to $47 at Morgan Stanley |
| December 15, 2025 1:38 pm | Gavin Clark-Gartner | Evercore ISI | $36.00 | $19.51 | TheFly | Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI |
| December 11, 2025 12:22 pm | — | Stifel Nicolaus | $39.00 | $19.69 | TheFly | Dyne Therapeutics price target raised to $39 from $36 at Stifel |
| December 10, 2025 11:49 am | — | Oppenheimer | $40.00 | $18.44 | TheFly | Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer |
| December 9, 2025 12:40 pm | William Pickering | Tudor Pickering | $23.00 | $19.09 | StreetInsider | Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group |
| December 9, 2025 11:49 am | — | Bernstein | $23.00 | $22.20 | TheFly | Dyne Therapeutics price target raised to $23 from $21 at Bernstein |
| December 8, 2025 5:06 pm | Michael E Ulz | Morgan Stanley | $50.00 | $22.20 | StreetInsider | Dyne Therapeutics (DYN) PT Raised to $50 at Morgan Stanley |
| December 8, 2025 2:26 pm | Brian Skorney | Robert W. Baird | $30.00 | $23.03 | StreetInsider | Baird Reiterates Outperform Rating on Dyne Therapeutics (DYN) |
| December 8, 2025 2:19 pm | Andrew Fein | H.C. Wainwright | $60.00 | $23.52 | TheFly | Dyne Therapeutics price target raised to $60 from $46 at H.C. Wainwright |
Latest News for DYN
Darwin Wealth Management LLC decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) by 33.6% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 115,267 shares of the company's stock after selling 58,250 shares during the period. Darwin Wealth Management LLC owned 0.08%
Aberdeen Group plc raised its position in Dyne Therapeutics, Inc. (NASDAQ: DYN) by 99.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,108,145 shares of the company's stock after acquiring an additional 551,412 shares during the period. Aberdeen
Dyne Therapeutics (NASDAQ: DYN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings. Profitability This table compares Dyne Therapeutics and MediWound's net
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care experts -
Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report)'s share price rose 4.4% during mid-day trading on Friday. The company traded as high as $18.39 and last traded at $18.5840. Approximately 898,531 shares were traded during mid-day trading, a decline of 59% from the average daily volume of 2,203,674 shares. The stock had previously closed
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DYN.
U.S. House Trading
No House trades found for DYN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.